Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
December 06, 2024 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging...
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering
November 25, 2024 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging...
Eyenovia Provides Update on Restructuring Efforts
November 22, 2024 07:00 ET
|
Eyenovia, Inc.
Avenue Capital agrees to Company’s deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues to evaluate a broad range of strategic...
Eyenovia Provides Update on Phase 3 CHAPERONE Study
November 15, 2024 07:00 ET
|
Eyenovia, Inc.
A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and...
Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024 16:05 ET
|
Eyenovia, Inc.
Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of...
Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th
November 07, 2024 07:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet...
Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®
October 23, 2024 07:00 ET
|
Eyenovia, Inc.
Publication in the Journal of Ocular Pharmacology and Therapeutics highlights the ability of the Optejet to achieve a therapeutic dose of medication with far less exposure to harmful preservatives ...
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
October 16, 2024 07:00 ET
|
Eyenovia, Inc.
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo,...
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
October 01, 2024 07:00 ET
|
Eyenovia, Inc.
NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced that the Company has commenced manufacturing of registration batches of...
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
September 27, 2024 08:30 ET
|
Eyenovia, Inc.
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in...